2.27
Innate Pharma Adr Borsa (IPHA) Ultime notizie
Arm Holdings PLC Releases Q2 2025 Financial Report Amid Market Challenges - The Globe and Mail
How strong is Innate Pharma S.A. Depositary Receipt company’s balance sheetSuperior risk-adjusted returns - Jammu Links News
Innate Pharma stock initiated with Buy rating at BTIG on cancer therapy potential - Investing.com
Non-Hodgkin’s Lymphoma Market Forecast to Surge with Growing Adoption of Targeted and Cell-Based Therapies | DelveInsight - GlobeNewswire Inc.
Innate Pharma (NASDAQ:IPHA) Trading 1.7% Higher – What’s Next? - Defense World
Exchange Traded Concepts LLC Has $112,000 Stock Position in Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) - Defense World
Why Kingsoft Cloud Holdings Stock Plummeted by Nearly 8% Today - The Globe and Mail
Should You Buy, Hold, or Sell PDD Holdings Stock Before Q1 Earnings? - The Globe and Mail
Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus - Investing.com India
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook By Investing.com - Investing.com South Africa
Innate Pharma reports promising preclinical results for cancer drug IPH4502 By Investing.com - Investing.com India
Innate Pharma stock surges on promising preclinical data By Investing.com - Investing.com South Africa
Innate Pharma reports promising preclinical results for cancer drug IPH4502 - Investing.com
H.C. Wainwright maintains $11 target on Innate Pharma stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $11 target on Innate Pharma stock - Investing.com
H.C. Wainwright maintains Buy rating on Innate Pharma stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Innate Pharma stock - Investing.com India
Innate Pharma Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances - Investing.com
AZN Stock Price and Chart — LSE:AZN - TradingView
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study - Nasdaq
Innate, Sanofi ink licensing deal for NK cells - MarketWatch
Innate Pharma: AstraZeneca To Discontinue INTERLINK-1 Monalizumab Combination Trial - Nasdaq
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities.com
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
Innate Pharma (IPHA) Stock Price, News & Analysis - MarketBeat
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):